BioSpace News Archive

Emmes today announced that Dr. Christine Dingivan has joined the company as its new president and chief executive officer.

Esperovax, the leader in Egress RD™ Oral Biologics has been awarded $607,000 in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Respons

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of

The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) has recently surpassed 700 participating medical centers and 700,000 procedures.

As October’s Efficient Collaborative Retail Marketing (ECRM) Conference approaches, both brands and retailers have begun to adjust to the new virtual platform.

The National Comprehensive Cancer Network® (NCCN®) today announced the publication of the organization’s first patient and caregiver resource focused on a childhood cancer type

Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System Next-generation technology provides easy, effective clot removal from peripheral arterial vasculature EDEN PRAIRIE, Minn.--( BUSINESS WIRE )-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Poun

Rediscovery Life Sciences, LLC (RLS), a clinical-stage biotechnology company, announced the closing of its most recent financing. The Series B financing was co-led by REX Health Ventures (the investment arm of UNC REX Healthcare) and Orlando Health Ventures. RLS will use the proceeds to fund a Phase 2 trial of suramin in diure

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac”, was approved by the National Medical Products Administration (NMPA) for clinical trial in adolescents and children in August 10 th , 2020. This randomized, double-blinded, an

Yulong Eco-Materials Limited / EV Biologics, Inc. (OTC PINK:YECO) today announced that it intends to list its Securitized Token Offering “STO” on the CryptoSX digital exchange.